FI126854B - Membraani, sen käyttö ja menetelmä membraanin valmistusta varten - Google Patents
Membraani, sen käyttö ja menetelmä membraanin valmistusta varten Download PDFInfo
- Publication number
- FI126854B FI126854B FI20136336A FI20136336A FI126854B FI 126854 B FI126854 B FI 126854B FI 20136336 A FI20136336 A FI 20136336A FI 20136336 A FI20136336 A FI 20136336A FI 126854 B FI126854 B FI 126854B
- Authority
- FI
- Finland
- Prior art keywords
- cells
- film
- membrane
- patterned
- cellulose
- Prior art date
Links
- 239000012528 membrane Substances 0.000 title claims description 344
- 238000000034 method Methods 0.000 title claims description 69
- 238000002360 preparation method Methods 0.000 title description 9
- 230000008569 process Effects 0.000 title description 6
- 229920001282 polysaccharide Polymers 0.000 claims description 170
- 150000004676 glycans Chemical class 0.000 claims description 169
- 239000005017 polysaccharide Substances 0.000 claims description 169
- 229920002678 cellulose Polymers 0.000 claims description 149
- 239000001913 cellulose Substances 0.000 claims description 148
- 210000004027 cell Anatomy 0.000 claims description 133
- 239000006185 dispersion Substances 0.000 claims description 93
- 239000004744 fabric Substances 0.000 claims description 77
- 239000010410 layer Substances 0.000 claims description 74
- 208000027418 Wounds and injury Diseases 0.000 claims description 51
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 51
- 206010052428 Wound Diseases 0.000 claims description 42
- 238000004519 manufacturing process Methods 0.000 claims description 32
- 238000001035 drying Methods 0.000 claims description 31
- 239000007788 liquid Substances 0.000 claims description 31
- 238000011282 treatment Methods 0.000 claims description 30
- 230000029663 wound healing Effects 0.000 claims description 26
- 210000000130 stem cell Anatomy 0.000 claims description 22
- 239000003795 chemical substances by application Substances 0.000 claims description 21
- 239000012736 aqueous medium Substances 0.000 claims description 19
- 239000002250 absorbent Substances 0.000 claims description 18
- 230000002745 absorbent Effects 0.000 claims description 18
- 210000003491 skin Anatomy 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 13
- 210000001519 tissue Anatomy 0.000 claims description 13
- 102000004127 Cytokines Human genes 0.000 claims description 12
- 108090000695 Cytokines Proteins 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 12
- 206010072170 Skin wound Diseases 0.000 claims description 11
- 206010061218 Inflammation Diseases 0.000 claims description 10
- 230000004054 inflammatory process Effects 0.000 claims description 10
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 9
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 9
- 239000012790 adhesive layer Substances 0.000 claims description 8
- 230000004888 barrier function Effects 0.000 claims description 8
- 210000002950 fibroblast Anatomy 0.000 claims description 8
- 230000035876 healing Effects 0.000 claims description 8
- 210000000987 immune system Anatomy 0.000 claims description 8
- 239000001963 growth medium Substances 0.000 claims description 7
- 210000002510 keratinocyte Anatomy 0.000 claims description 7
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 7
- 230000001225 therapeutic effect Effects 0.000 claims description 7
- 230000000735 allogeneic effect Effects 0.000 claims description 6
- 239000012867 bioactive agent Substances 0.000 claims description 6
- 235000014633 carbohydrates Nutrition 0.000 claims description 6
- 210000002889 endothelial cell Anatomy 0.000 claims description 6
- 239000011159 matrix material Substances 0.000 claims description 6
- 238000004377 microelectronic Methods 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 6
- 238000003860 storage Methods 0.000 claims description 6
- 108010085895 Laminin Proteins 0.000 claims description 5
- 102000007547 Laminin Human genes 0.000 claims description 5
- 210000001185 bone marrow Anatomy 0.000 claims description 5
- 210000002798 bone marrow cell Anatomy 0.000 claims description 5
- 239000000872 buffer Substances 0.000 claims description 5
- 150000001720 carbohydrates Chemical class 0.000 claims description 5
- 210000001612 chondrocyte Anatomy 0.000 claims description 5
- 210000004443 dendritic cell Anatomy 0.000 claims description 5
- 210000002919 epithelial cell Anatomy 0.000 claims description 5
- 230000012010 growth Effects 0.000 claims description 5
- 210000000442 hair follicle cell Anatomy 0.000 claims description 5
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 5
- 210000004408 hybridoma Anatomy 0.000 claims description 5
- 238000000338 in vitro Methods 0.000 claims description 5
- 150000002632 lipids Chemical class 0.000 claims description 5
- 210000000663 muscle cell Anatomy 0.000 claims description 5
- 239000002121 nanofiber Substances 0.000 claims description 5
- 210000002569 neuron Anatomy 0.000 claims description 5
- 230000003169 placental effect Effects 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 210000000329 smooth muscle myocyte Anatomy 0.000 claims description 5
- 108010067306 Fibronectins Proteins 0.000 claims description 4
- 102000016359 Fibronectins Human genes 0.000 claims description 4
- 230000021164 cell adhesion Effects 0.000 claims description 4
- 238000012423 maintenance Methods 0.000 claims description 4
- 238000000059 patterning Methods 0.000 claims description 4
- 239000002504 physiological saline solution Substances 0.000 claims description 4
- 239000008213 purified water Substances 0.000 claims description 4
- 238000011084 recovery Methods 0.000 claims description 4
- 230000036573 scar formation Effects 0.000 claims description 4
- 231100000075 skin burn Toxicity 0.000 claims description 4
- 239000008223 sterile water Substances 0.000 claims description 4
- 230000000451 tissue damage Effects 0.000 claims description 4
- 231100000827 tissue damage Toxicity 0.000 claims description 4
- 102000012422 Collagen Type I Human genes 0.000 claims description 3
- 108010022452 Collagen Type I Proteins 0.000 claims description 3
- 102000000503 Collagen Type II Human genes 0.000 claims description 3
- 108010041390 Collagen Type II Proteins 0.000 claims description 3
- 102000004266 Collagen Type IV Human genes 0.000 claims description 3
- 108010042086 Collagen Type IV Proteins 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 102100035140 Vitronectin Human genes 0.000 claims description 3
- 108010031318 Vitronectin Proteins 0.000 claims description 3
- 229940035676 analgesics Drugs 0.000 claims description 3
- 239000000730 antalgic agent Substances 0.000 claims description 3
- 230000000843 anti-fungal effect Effects 0.000 claims description 3
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 3
- 230000000840 anti-viral effect Effects 0.000 claims description 3
- 229940121375 antifungal agent Drugs 0.000 claims description 3
- 239000000427 antigen Substances 0.000 claims description 3
- 102000036639 antigens Human genes 0.000 claims description 3
- 108091007433 antigens Proteins 0.000 claims description 3
- 230000003115 biocidal effect Effects 0.000 claims description 3
- 108010015046 cell aggregation factors Proteins 0.000 claims description 3
- 239000002872 contrast media Substances 0.000 claims description 3
- 238000002059 diagnostic imaging Methods 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 238000005530 etching Methods 0.000 claims description 3
- 239000012634 fragment Substances 0.000 claims description 3
- 230000003232 mucoadhesive effect Effects 0.000 claims description 3
- 108020004707 nucleic acids Proteins 0.000 claims description 3
- 150000007523 nucleic acids Chemical class 0.000 claims description 3
- 102000039446 nucleic acids Human genes 0.000 claims description 3
- 230000002188 osteogenic effect Effects 0.000 claims description 3
- 230000002093 peripheral effect Effects 0.000 claims description 3
- 210000000577 adipose tissue Anatomy 0.000 claims description 2
- 235000013311 vegetables Nutrition 0.000 claims description 2
- 238000000465 moulding Methods 0.000 claims 3
- 239000003173 antianemic agent Substances 0.000 claims 2
- 239000002318 adhesion promoter Substances 0.000 claims 1
- 229940035674 anesthetics Drugs 0.000 claims 1
- 230000000845 anti-microbial effect Effects 0.000 claims 1
- 210000000601 blood cell Anatomy 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 238000010276 construction Methods 0.000 claims 1
- 239000003193 general anesthetic agent Substances 0.000 claims 1
- -1 immune stimulants Substances 0.000 claims 1
- 229960001438 immunostimulant agent Drugs 0.000 claims 1
- 235000015097 nutrients Nutrition 0.000 claims 1
- 210000005167 vascular cell Anatomy 0.000 claims 1
- 235000010980 cellulose Nutrition 0.000 description 118
- 125000000129 anionic group Chemical group 0.000 description 18
- 239000000463 material Substances 0.000 description 18
- 239000002994 raw material Substances 0.000 description 16
- 102100029647 Apoptosis-associated speck-like protein containing a CARD Human genes 0.000 description 15
- 101000728679 Homo sapiens Apoptosis-associated speck-like protein containing a CARD Proteins 0.000 description 15
- 239000000835 fiber Substances 0.000 description 13
- 239000000523 sample Substances 0.000 description 13
- 241000196324 Embryophyta Species 0.000 description 12
- 238000000576 coating method Methods 0.000 description 12
- 230000002829 reductive effect Effects 0.000 description 12
- 239000000017 hydrogel Substances 0.000 description 11
- 238000001878 scanning electron micrograph Methods 0.000 description 11
- 239000011248 coating agent Substances 0.000 description 10
- 229910052751 metal Inorganic materials 0.000 description 10
- 239000002184 metal Substances 0.000 description 10
- 238000012876 topography Methods 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 229920001046 Nanocellulose Polymers 0.000 description 9
- 230000006378 damage Effects 0.000 description 9
- 208000014674 injury Diseases 0.000 description 9
- 239000004033 plastic Substances 0.000 description 9
- 229920003023 plastic Polymers 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 210000004207 dermis Anatomy 0.000 description 8
- 210000001724 microfibril Anatomy 0.000 description 8
- 239000002245 particle Substances 0.000 description 8
- 239000011148 porous material Substances 0.000 description 7
- 206010061592 cardiac fibrillation Diseases 0.000 description 6
- 238000005266 casting Methods 0.000 description 6
- 230000002500 effect on skin Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 210000002744 extracellular matrix Anatomy 0.000 description 6
- 230000002600 fibrillogenic effect Effects 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 238000003825 pressing Methods 0.000 description 6
- 231100000241 scar Toxicity 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 208000032544 Cicatrix Diseases 0.000 description 5
- 239000004952 Polyamide Substances 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 230000001464 adherent effect Effects 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 210000002808 connective tissue Anatomy 0.000 description 5
- 238000012258 culturing Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 229920002647 polyamide Polymers 0.000 description 5
- 230000037387 scars Effects 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 229920002101 Chitin Polymers 0.000 description 4
- 229920001661 Chitosan Polymers 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical class CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 102000009123 Fibrin Human genes 0.000 description 4
- 108010073385 Fibrin Proteins 0.000 description 4
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 4
- 229920002488 Hemicellulose Polymers 0.000 description 4
- 238000011529 RT qPCR Methods 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000012752 auxiliary agent Substances 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000007547 defect Effects 0.000 description 4
- 210000002615 epidermis Anatomy 0.000 description 4
- 229950003499 fibrin Drugs 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- 210000002536 stromal cell Anatomy 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 238000004627 transmission electron microscopy Methods 0.000 description 4
- 239000002023 wood Substances 0.000 description 4
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 3
- 206010016654 Fibrosis Diseases 0.000 description 3
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 3
- UGXQOOQUZRUVSS-ZZXKWVIFSA-N [5-[3,5-dihydroxy-2-(1,3,4-trihydroxy-5-oxopentan-2-yl)oxyoxan-4-yl]oxy-3,4-dihydroxyoxolan-2-yl]methyl (e)-3-(4-hydroxyphenyl)prop-2-enoate Chemical compound OC1C(OC(CO)C(O)C(O)C=O)OCC(O)C1OC1C(O)C(O)C(COC(=O)\C=C\C=2C=CC(O)=CC=2)O1 UGXQOOQUZRUVSS-ZZXKWVIFSA-N 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 229940072056 alginate Drugs 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 229920006321 anionic cellulose Polymers 0.000 description 3
- 229920000617 arabinoxylan Polymers 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 210000001608 connective tissue cell Anatomy 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000001212 derivatisation Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 210000001671 embryonic stem cell Anatomy 0.000 description 3
- 210000004700 fetal blood Anatomy 0.000 description 3
- 230000004761 fibrosis Effects 0.000 description 3
- 238000000227 grinding Methods 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- GDOPTJXRTPNYNR-UHFFFAOYSA-N methyl-cyclopentane Natural products CC1CCCC1 GDOPTJXRTPNYNR-UHFFFAOYSA-N 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 108700005457 microfibrillar Proteins 0.000 description 3
- 229920001277 pectin Polymers 0.000 description 3
- 235000010987 pectin Nutrition 0.000 description 3
- 239000001814 pectin Substances 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- LCSKNASZPVZHEG-UHFFFAOYSA-N 3,6-dimethyl-1,4-dioxane-2,5-dione;1,4-dioxane-2,5-dione Chemical group O=C1COC(=O)CO1.CC1OC(=O)C(C)OC1=O LCSKNASZPVZHEG-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 229920003319 Araldite® Polymers 0.000 description 2
- 235000018185 Betula X alpestris Nutrition 0.000 description 2
- 235000018212 Betula X uliginosa Nutrition 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 101100447432 Danio rerio gapdh-2 gene Proteins 0.000 description 2
- 102000016911 Deoxyribonucleases Human genes 0.000 description 2
- 108010053770 Deoxyribonucleases Proteins 0.000 description 2
- 206010063560 Excessive granulation tissue Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 101150112014 Gapdh gene Proteins 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 229920002201 Oxidized cellulose Polymers 0.000 description 2
- 239000004809 Teflon Substances 0.000 description 2
- 229920006362 Teflon® Polymers 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 229940124326 anaesthetic agent Drugs 0.000 description 2
- 230000003444 anaesthetic effect Effects 0.000 description 2
- 239000004037 angiogenesis inhibitor Substances 0.000 description 2
- 230000002491 angiogenic effect Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 229940030225 antihemorrhagics Drugs 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 229940125715 antihistaminic agent Drugs 0.000 description 2
- 102000015736 beta 2-Microglobulin Human genes 0.000 description 2
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000010924 continuous production Methods 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000000604 cryogenic transmission electron microscopy Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 229910003460 diamond Inorganic materials 0.000 description 2
- 239000010432 diamond Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 210000001126 granulation tissue Anatomy 0.000 description 2
- 239000011121 hardwood Substances 0.000 description 2
- 239000002874 hemostatic agent Substances 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 229960002725 isoflurane Drugs 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 229940107304 oxidized cellulose Drugs 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000007261 regionalization Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000037390 scarring Effects 0.000 description 2
- 239000011122 softwood Substances 0.000 description 2
- 230000003746 surface roughness Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- JNLCUVJKTXKKSG-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;lead Chemical compound [Pb].OC(=O)CC(O)(C(O)=O)CC(O)=O JNLCUVJKTXKKSG-UHFFFAOYSA-N 0.000 description 1
- 244000283070 Abies balsamea Species 0.000 description 1
- 235000007173 Abies balsamea Nutrition 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 244000198134 Agave sisalana Species 0.000 description 1
- 235000011624 Agave sisalana Nutrition 0.000 description 1
- 241000609240 Ambelania acida Species 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 241000209763 Avena sativa Species 0.000 description 1
- 235000007558 Avena sp Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229920002749 Bacterial cellulose Polymers 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 241000219495 Betulaceae Species 0.000 description 1
- 240000008564 Boehmeria nivea Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
- 229920003043 Cellulose fiber Polymers 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 240000000491 Corchorus aestuans Species 0.000 description 1
- 235000011777 Corchorus aestuans Nutrition 0.000 description 1
- 235000010862 Corchorus capsularis Nutrition 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 206010011985 Decubitus ulcer Diseases 0.000 description 1
- 206010061619 Deformity Diseases 0.000 description 1
- 235000014466 Douglas bleu Nutrition 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 244000004281 Eucalyptus maculata Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000219146 Gossypium Species 0.000 description 1
- 240000000797 Hibiscus cannabinus Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 241000218652 Larix Species 0.000 description 1
- 235000005590 Larix decidua Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 235000004431 Linum usitatissimum Nutrition 0.000 description 1
- 240000006240 Linum usitatissimum Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 240000000907 Musa textilis Species 0.000 description 1
- 238000011794 NU/NU nude mouse Methods 0.000 description 1
- 229920002302 Nylon 6,6 Polymers 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 241000218657 Picea Species 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000209504 Poaceae Species 0.000 description 1
- 241000219000 Populus Species 0.000 description 1
- 241000183024 Populus tremula Species 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 240000001416 Pseudotsuga menziesii Species 0.000 description 1
- 235000005386 Pseudotsuga menziesii var menziesii Nutrition 0.000 description 1
- 229920001131 Pulp (paper) Polymers 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- CGNLCCVKSWNSDG-UHFFFAOYSA-N SYBR Green I Chemical compound CN(C)CCCN(CCC)C1=CC(C=C2N(C3=CC=CC=C3S2)C)=C2C=CC=CC2=[N+]1C1=CC=CC=C1 CGNLCCVKSWNSDG-UHFFFAOYSA-N 0.000 description 1
- 241000209056 Secale Species 0.000 description 1
- 235000007238 Secale cereale Nutrition 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 238000003917 TEM image Methods 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 241000186514 Warburgia ugandensis Species 0.000 description 1
- 229920002522 Wood fibre Polymers 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001299 aldehydes Chemical group 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 238000000089 atomic force micrograph Methods 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 210000001142 back Anatomy 0.000 description 1
- 239000005016 bacterial cellulose Substances 0.000 description 1
- 239000010905 bagasse Substances 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000003490 calendering Methods 0.000 description 1
- 235000009120 camo Nutrition 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000005607 chanvre indien Nutrition 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- MCBBFDNTCVNDCE-UHFFFAOYSA-N cyclopenta-1,3-diene cyclopenta-2,4-diene-1-carbonyl cyanide iron(2+) Chemical compound [Fe++].c1cc[cH-]c1.O=C(C#N)[c-]1cccc1 MCBBFDNTCVNDCE-UHFFFAOYSA-N 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000004049 embossing Methods 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- IINOLFPQEZQVMB-UHFFFAOYSA-N ethanol;1,2-xylene Chemical group CCO.CC1=CC=CC=C1C IINOLFPQEZQVMB-UHFFFAOYSA-N 0.000 description 1
- 238000006266 etherification reaction Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000002657 fibrous material Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 244000144992 flock Species 0.000 description 1
- 238000001595 flow curve Methods 0.000 description 1
- 229920002313 fluoropolymer Polymers 0.000 description 1
- 239000004811 fluoropolymer Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 239000011487 hemp Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 229940101737 isoflo Drugs 0.000 description 1
- 238000000608 laser ablation Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003534 oscillatory effect Effects 0.000 description 1
- 229910052762 osmium Inorganic materials 0.000 description 1
- SYQBFIAQOQZEGI-UHFFFAOYSA-N osmium atom Chemical compound [Os] SYQBFIAQOQZEGI-UHFFFAOYSA-N 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000002940 repellent Effects 0.000 description 1
- 239000005871 repellent Substances 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229950003937 tolonium Drugs 0.000 description 1
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000010246 ultrastructural analysis Methods 0.000 description 1
- 239000013026 undiluted sample Substances 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000010388 wound contraction Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/28—Polysaccharides or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/00051—Accessories for dressings
- A61F13/00063—Accessories for dressings comprising medicaments or additives, e.g. odor control, PH control, debriding, antimicrobic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/00987—Apparatus or processes for manufacturing non-adhesive dressings or bandages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/01—Non-adhesive bandages or dressings
- A61F13/01008—Non-adhesive bandages or dressings characterised by the material
- A61F13/01012—Non-adhesive bandages or dressings characterised by the material being made of natural material, e.g. cellulose-, protein-, collagen-based
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/225—Mixtures of macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/36—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing microorganisms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/20—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
- A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
- A61L27/3834—Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L1/00—Compositions of cellulose, modified cellulose or cellulose derivatives
- C08L1/02—Cellulose; Modified cellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00089—Wound bandages
- A61F2013/00157—Wound bandages for burns or skin transplants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/64—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/12—Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/18—Modification of implant surfaces in order to improve biocompatibility, cell growth, fixation of biomolecules, e.g. plasma treatment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Materials Engineering (AREA)
- Medicinal Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Cell Biology (AREA)
- Vascular Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Developmental Biology & Embryology (AREA)
- Zoology (AREA)
- Botany (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Manufacturing & Machinery (AREA)
- Polymers & Plastics (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Materials For Medical Uses (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Medicinal Preparation (AREA)
Claims (43)
1. Kalvo, joka käsittää kasviperäistä jatkuvaksi järjestelyksi järjestynyttä nanosäikeistä selluloosaa, johon kalvoon kuuluu vähintään yksi mallikuvioitu alue, jossa on mikromittakaavan syvennyksiä ja/tai ulkonemia vähintään kalvon yhdellä puolella, jossa mallikuvioitu alue käsittää yksiköiden toistuvan mallikuvion, jonka yksikön vähintään yksi ulottuvuus on alueella 1-500 pm kalvon tasoa pitkin.
2. Patenttivaatimuksen 1 mukainen kalvo, jossa syvennykset eivät ulotu kalvon koko paksuuden läpi.
3. Jonkin patenttivaatimuksista 1-2 mukainen kalvo, jossa vähintään yhdellä kalvon puolella on mallikuvioitu alue, jossa on mikromittakaavan syvennyksiä ja/tai ulkonemia jatkuvina, toisiinsa yhdistyneinä yksikköinä.
4. Jonkin patenttivaatimuksista 1-3 mukainen kalvo, jossa mallikuvioidun alueen lukukeskimääräinen paksuus on 100 nm - 100 pm, edullisesti 200 nm - 10 pm, ja kaikkein edullisimmin 1-10 pm.
5. Jonkin patenttivaatimuksista 1-4 mukainen kalvo, jossa mallikuvioitu alue käsittää yksiköiden toistuvan mallikuvion, jotka yksiköt yhdistää toisiinsa yhteinen seinä, jonka leveys on 10 nm - 10 pm, edullisesti 100 nm - 1 pm, kaikkein edullisimmin 200 nm - 1 pm.
6. Jonkin patenttivaatimuksista 1-5 mukainen kalvo, jonka kalvon paksuus on 1-300 pm, edullisesti 10-100 pm, kaikkein edullisimmin 20-60 pm.
7. Jonkin patenttivaatimuksista 1-6 mukainen kalvo, joka kalvo sisältää 90-100 % kuivapainosta kasviperäistä nanosäikeistä selluloosaa, edullisesti 95-100 % kuivapainosta kasviperäistä nanosäikeistä selluloosaa, edullisemmin 99-100 % kuivapainosta nanosäikeistä selluloosaa.
8. Jonkin patenttivaatimuksista 1-7 mukainen kalvo, jossa kasviperäinen nanosäikeinen selluloosa on johdannainen kasviperäisestä nanosäkeisestä selluloosasta.
9. Jonkin patenttivaatimuksista 1-8 mukainen kalvo, jossa mainittu kasviperäinen nanosäikeinen selluloosa on hajotettu mekaanisesti.
10. Jonkin patenttivaatimuksista 1-9 mukainen kalvo, jossa kasviperäinen nanosäikeinen selluloosa sisältää polysakkaridinanosäikeitä ja/tai nanosäikeiden kimppuja, joiden lukukeskimääräinen halkaisija on 1-500 nm, edullisesti 2-200 nm.
11. Jonkin patenttivaatimuksista 1-10 mukainen kalvo, jonka kalvon kummatkin puolet on mallikuvioitu.
12. Menetelmä kalvon, joka käsittää jatkuvaksi järjestelyksi järjestynyttä kasviperäistä nanosäikeistä selluloosaa, jonka kalvon vähintään yhdellä puolella on vähintään yksi mallikuvioitu alue, jossa on mikromittakaavan syvennyksiä ja/tai ulkonemia, valmistamiseksi, johon menetelmään kuuluu vaihe, jossa saadaan aikaan kasviperäisen nanosäikeisen selluloosan dispersio; sekä vaihe, joka on valittu seuraavista: a. kasviperäisen nanosäikeisen selluloosan dispersion valaminen valualustalle, jossa on vähintään yksi mallikuvioitu alue, jossa on mikromittakaavan syvennyksiä ja/tai ulkonemia, jossa valualusta käsittää yksiköiden toistuvan mallikuvion, jonka yksikön vähintään yksi ulottuvuus on alueella 1-500 pm kalvon tasoa pitkin, kuivausta ja muodostuneen kalvon, jossa on vähintään yksi mallikuvioitu alue, jossa on mikromittakaavan syvennyksiä ja/tai ulkonemia käänteisenä järjestelynä valualustaan verrattuna, poiston; ja b. kasviperäisen nanosäikeisen selluloosadispersion muuntaminen kalvoksi, kalvon vähintään yhden alueen syövytys vähintään yhden, mikromittakaavan syvennyksiä ja/tai ulkonemia käsittävän mallikuvioidun alueen aikaansaamiseksi, jossa mallikuvioitu alue käsittää yksiköiden toistuvan mallikuvion, jonka yksikön vähintään yksi ulottuvuus on alueella 1-500 pm kalvon tasoa pitkin.
13. Menetelmä kalvon, joka käsittää kasviperäistä jatkuvaksi järjestelyksi järjestynyttä nanosäikeistä selluloosaa, jonka kalvon vähintään yhdellä puolella on vähintään yksi mallikuvioitu alue, jossa on mikromittakaavan syvennyksiä ja/tai ulkonemia, valmistamiseksi, johon menetelmään kuuluvat vaiheet, jossa a. saadaan aikaan kasviperäisen nanosäikeisen selluloosan dispersio mallikuvioidun suodattimen päälle, jossa on mikromittakaavan syvennyksiä ja/tai ulkonemia, edullisesti mallikuvioidun suodatinkankaan päälle, jossa mallikuvioitu suodatin käsittää yksiköiden toistuvan mallikuvion, jonka yksikön vähintään yksi ulottuvuus on alueella 1-500 pm kalvon tasoa pitkin; b. kasviperäisen nanosäikeisen selluloosan dispersiosta valutetaan pois nestettä mallikuvioidun suodattimen läpi muuttuvan paineen vaikutuksesta, joka suodatin on olennaisesti nanosäikeisen selluloosan säikeitä läpäisemätöntä, mutta joka läpäisee nestettä niin, että mallikuvioidun suodattimen päälle muodostuu kalvo; c. valinnaisesti kalvo kuivataan samalla kun nestettä poistetaan jatkuvasti kasviperäisen nanosäikeisen selluloosan dispersiosta; ja d. valinnaisesti kalvo poistetaan mallikuvioidulta suodattimelta, jolloin saadaan kasviperäistä nanosäikeistä selluloosaa sisältävä kalvo, jossa on mikromittakaavan syvennyksiä ja/tai ulkonemia käänteisenä järjestelynä mikromittakaavan syvennyksiä ja/tai ulkonemia käsittävään mallikuvioituun suodattimeen nähden.
14. Patenttivaatimuksen 12 tai 13 mukainen menetelmä, jossa kasviperäisen nanosäikeisen selluloosan dispersio saadaan hajottamalla selluloosa, valinnaisesti selluloosan mekaanisella hajotuksella.
15. Patenttivaatimuksen 13 mukainen menetelmä, jossa vaiheeseen d. kuuluu vaihtoehtoisesti vaihe, jossa mallikuvioitu suodatin pidetään kalvotuotteen muodostavana osana, joka kalvotuote käsittää mallikuvioidun suodattimen ja kasviperäisen nanosäikeisen selluloosakalvon.
16. Jonkin patenttivaatimuksista 13-15 mukainen menetelmä, jossa kalvoarkki kuivataan kohdistamalla kalvoon lämpöä siten, että vaiheessa c. kasviperäisen nanosäikeisen selluloosakalvo saatetaan kosketukseen valinnaisesti tarttumattomalla kerroksella pinnoitetun kuumennetun pinnan kanssa.
17. Patenttivaatimuksen 16 mukainen menetelmä, jossa kuumennettu pinta painetaan kalvoa vasten niin, että kalvoarkkiin saadaan aikaan painetta, joka aiheuttaa vähintään osittain paine-eron mallikuvioidun suodattimen poikki.
18. Jonkin patenttivaatimuksista 14-17 mukainen menetelmä, jossa kuumennettu pinta ja/tai tarttumaton kerros on kuvioitu ja käänteinen kuvio siirtyy kalvon sille puolelle, joka on kuumennettua pintaa ja/tai tarttumatonta kerrosta kohden, kun kuumennettu pinta painetaan kalvoa vasten.
19. Jonkin patenttivaatimuksista 14-18 mukainen menetelmä, jossa lämpöä kohdistetaan kasviperäiseen nanosäikeiseen selluloosakalvoon kuumennetusta pinnasta kuumennetun pinnan ja kasviperäisen nanosäikeisen selluloosan kalvon väliin sijoitetun kerroksen kuten mallikuvioidun suodattimen tai rakennekerroksen, johon kasviperäinen nanosäikeisen selluloosakalvo on tarkoitus laminoida, läpi.
20. Jonkin patenttivaatimuksista 14-20 mukainen menetelmä, jossa kasviperäisen nanosäikeisen selluloosan dispersio saatetaan liikkuvan mallikuvioidun suodattimen päälle jatkuvana verkkona, ja jatkuva mallikuvioitu kalvo tuotetaan siirtämällä jatkuva verkko liikkuvan mallikuvioidun suodattimen päälle eri prosessivaiheissa, ja mallikuvioitu kalvo erotetaan mallikuvioidusta suodattimesta.
21. Jonkin patenttivaatimuksista 12-20 mukainen menetelmä, jossa kasviperäisen nanosäikeisen selluloosan varastomoduuli on alueella 1-50 Pa, edullisesti 3-20 Pa, vesidispersiossa, jonka pitoisuus on 0,5 paino-%.
22. Laite, joka käsittää soluja sekä kalvon, joka käsittää kasviperäistä jatkuvaksi järjestelyksi järjestynyttä nanosäikeistä selluloosaa, jonka kalvon vähintään yhdellä puolella on vähintään yksi mallikuvioitu alue, jossa on mikromittakaavan syvennyksiä ja/tai ulkonemia, jossa mallikuvioitu alue käsittää yksiköiden toistuvan mallikuvion, jonka yksikön vähintään yksi ulottuvuus on alueella 1-500 pm kalvon tasoa pitkin.
23. Patenttivaatimuksen 22 mukainen laite, jossa kalvo on jonkin patenttivaatimuksista 1-11 mukainen kalvo.
24. Jonkin patenttivaatimuksista 22-23 mukainen laite, jossa solut on lyofilisoitu.
25. Jonkin patenttivaatimuksista 22-24 mukainen laite, joka laite on kuivassa muodossa.
26. Jonkin patenttivaatimuksista 22-25 mukainen laite, jossa mikromittakaavan syvennysten ja/tai ulkonemien mitat sallivat solujen asettumisen kalvon syvennyksiin ja/tai sallivat solujen kiinnittymisen olennaisesti kalvon ulkonemien päälle.
27. Jonkin patenttivaatimuksista 22-26 mukainen laite, joka käsittää vesipohjaista väliainetta imeytyneenä kalvon sisään, joka vesipohjainen väliaine sisältää vettä, steriiliä vettä, puhdistettua vettä, fysiologista suolaliuosta, fysiologista puskuria, viljelyalustaa, ravintoaineita ja/tai bioaktiivista ainetta, tai niiden yhdistelmiä.
28. Patenttivaatimuksen 27 mukainen laite, jossa mainittu bioaktiivinen aine on valittu ryhmästä, joka koostuu proteiineista, peptideistä, hiilihydraateista, lipideistä, nukleiinihapoista ja niiden fragmenteista, viruksia torjuvista yhdisteistä, tulehdusta torjuvista yhdisteistä, antibioottisista yhdisteistä kuten sieniä torjuvista ja bakteereita torjuvista yhdisteistä, soluja erilaistavista aineista, analgeeteista, varjoaineista lääketieteellistä diagnostista kuvantamista varten, entsyymeistä, sytokiineista, anestesia-aineista, antihistamiineista, immuunijärjestelmään vaikuttavista aineista, immuunijärjestelmää kiihottavista aineista, hemostaattisista aineista, hormoneista, angiogeenisista tai anti-angiogeenisista aineista, hermovälittäjäaineista, hoitavista oligonukleotideista, virushiukkasista, vektoreista, kasvutekijöistä, retinoideista, solujen tarttumistekijöistä, osteogeenisistä tekijöistä, vasta-aineista, antigeeneistä, peptideistä, soluista ja niiden johdannaisista, soluton matriisi mukaan lukien.
29. Jonkin patenttivaatimuksista 22-28 mukainen laite, jossa vähintään osa kalvon vähintään yhdestä puolesta on pinnoitettu solujen tarttumista edistävällä aineella tai siihen on sidottu kemiallisesti solujen tarttumista edistävää ainetta, joka on valittu ryhmästä, joka koostuu kaiken tyyppisistä, solun ulkopuolisen matriisin proteiineista kuten laminiinista, fibronektiinistä, vitronektiinistä, I-tyypin kollageenista, II-tyypin kollageenista ja IV-tyypin kollageenista ja/tai niiden yhdistelmistä tai jakeista tai kompleksisista seoksista.
30. Jonkin patenttivaatimuksista 22-29 mukainen laite, joka käsittää lisäksi yhden tai useamman, biolääketieteellisen laitteen vähintään osan kuten laitteen keskusalueen tai reuna-alueen yli ulottuvan kerroksen, joka yksi tai useampi kerros on valittu seuraavista: tukikerros, taustakerros, kosteutta pidättävä kerros, kosteutta imevä kerros, kosteudenestokerros, kaasunestokerros, hajuja imevä kerros, lääkeainetta sisältävä kerros, liima-ainekerros ja/tai limakalvoon tarttuva kerros.
31. Jonkin patenttivaatimuksista 22-30 mukainen laite, jossa soluja ovat autologiset solut, allogeeniset solut, kantasolut, kantamuotosolut, esiastesolut, sidekudoksen solut, epiteelisolut, lihassolut, hermosolut, endoteelisolut, fibroblastit, keratinosyytit, sileiden lihasten solut, peruskudossolut, mesenkymaaliset solut, napanuoran verisolut, alkion kantasolut, indusoidut monikykyiset solut, istukkasolut, luuytimestä peräisin olevat solut, immuunijärjestelmän solut, hematopoieettiset solut, dendriittisolut, hiusfollikkelin solut, kondrosyytit, hybridomasolut ja/tai niiden yhdistelmät.
32. Jonkin patenttivaatimuksista 22-31 mukainen laite, jossa solut ovat haavan parantamista ajatellen hoitavasti käyttökelpoisia soluja, edullisesti mesenkymaalisia kantasoluja, rasvakudoksesta peräisin olevia kantasoluja tai luuytimestä peräisin olevia kantasoluja.
33. Menetelmä laitteen, joka käsittää kasviperäistä jatkuvaksi järjestelyksi järjestynyttä nanosäikeistä selluloosaa, jonka kalvon vähintään yhdellä puolella on vähintään yksi mallikuvioitu alue, jossa on mikromittakaavan syvennyksiä ja/tai ulkonemia, jossa mallikuvioitu alue käsittää yksiköiden toistuvan mallikuvion, jonka yksikön vähintään yksi ulottuvuus on alueella 1-500 pm kalvon tasoa pitkin, valmistamiseksi, joka menetelmä käsittää vaiheet, joissa a. saadaan aikaan soluja; b. vesipohjaista väliainetta absorboidaan kasviperäistä jatkuvaksi järjestelyksi järjestynyttä nanosäikeistä selluloosaa käsittävään kalvoon, jonka kalvon vähintään yhdellä puolella on vähintään yksi mallikuvioitu alue, jossa on mikromittakaavan syvennyksiä ja/tai ulkonemia, c. solut siirretään kalvoon; ja d. soluja inkuboidaan olosuhteissa, jotka sallivat solujen kiinnittymisen kalvon pinnalle, ja solujen ylläpito tai erilaistumaton tai erilaistunut kasvu sallitaan.
34. Patenttivaatimuksen 33 mukainen menetelmä, jossa soluja ovat autologiset solut, allogeeniset solut, kantasolut, kantamuotosolut, esiastesolut, sidekudoksen solut, epiteelisolut, lihassolut, hermosolut, endoteelisolut, fibroblastit, keratinosyytit, sileiden lihasten solut, peruskudossolut, mesenkymaaliset solut, napanuoran verisolut, alkion kantasolut, indusoidut monikykyiset solut, istukkasolut, luuytimestä peräisin olevat solut, immuunijärjestelmän solut, hematopoieettiset solut, dendriittisolut, hiusfollikkelin solut, kondrosyytit, hybridomasolut ja/tai niiden yhdistelmät.
35. Jonkin patenttivaatimuksista 33-34 mukainen menetelmä, jossa solut on lyofilisoitu.
36. Jonkin patenttivaatimuksista 33-35 mukainen menetelmä, jossa vaiheet b ja c toteutetaan samanaikaisesti.
37. Jonkin patenttivaatimuksista 33-35 mukainen menetelmä, jossa kalvo on jonkin patenttivaatimuksista 1-11 mukainen kalvo.
38. Jonkin patenttivaatimuksista 1-11 mukainen kalvo tai jonkin patenttivaatimuksista 22-32 mukainen laite käytettäväksi hoitosovelluksessa.
39. Jonkin patenttivaatimuksista 1-11 mukainen kalvo tai jonkin patenttivaatimuksista 22-32 mukainen laite käytettäväksi haavojen, edullisesti ihohaavojen tai ihon palohaavojen hoitoon.
40. Jonkin patenttivaatimuksista 22-32 mukainen laite, joka käsittää rasvakudoksesta peräisin olevia kantasoluja tai luuytimestä peräisin olevia kantasoluja, käytettäväksi tulehduksen, immuunihyljinnän, tai arven muodostumisen estoon ihokudosvauriosta toipumisen aikana.
41. Jonkin patenttivaatimuksista 1-11 mukaisen kalvon käyttö kudoksen rakennuksessa in vitro, mikrofluidiikassa tai mikroelektroniikassa.
42. Yhdistelmäpakkaus, joka sisältää jonkin patenttivaatimuksista 1-11 mukaisen kalvon, valinnaisesti vesipohjaista väliainetta sekä ohjeet kudoksen rakennuksessa, mikrofluidiikassa tai mikroelektroniikassa käyttöä varten.
43. Patenttivaatimuksen 42 mukainen yhdistelmäpakkaus, jossa kalvo on steriili ja pakattu aseptisesti, valinnainen vesipohjainen väliaine on steriili ja se toimitetaan kalvoon absorboituna tai erillisessä lääkepullossa, ja käyttöohjeet on tarkoitettu käyttöön yhdessä hoitavasti käyttökelpoisten solujen kanssa haavan parantamista varten.
Priority Applications (12)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI20136336A FI126854B (fi) | 2013-12-30 | 2013-12-30 | Membraani, sen käyttö ja menetelmä membraanin valmistusta varten |
| EP14828042.3A EP3089765B1 (en) | 2013-12-30 | 2014-12-30 | Biomedical device |
| DK14828042.3T DK3089765T3 (da) | 2013-12-30 | 2014-12-30 | Biomedicinsk indretning |
| US15/108,943 US20160325008A1 (en) | 2013-12-30 | 2014-12-30 | Biomedical device |
| PCT/FI2014/051061 WO2015101711A1 (en) | 2013-12-30 | 2014-12-30 | Patterned membrane |
| PCT/FI2014/051062 WO2015101712A1 (en) | 2013-12-30 | 2014-12-30 | Biomedical device |
| JP2016543634A JP6636926B2 (ja) | 2013-12-30 | 2014-12-30 | 生体医学的装置 |
| CN201480071650.3A CN106132447A (zh) | 2013-12-30 | 2014-12-30 | 生物医学装置 |
| US15/109,068 US20160325006A1 (en) | 2013-12-30 | 2014-12-30 | Patterned membrane |
| CN201480071655.6A CN105873621A (zh) | 2013-12-30 | 2014-12-30 | 图案化的膜 |
| JP2016543668A JP6576933B2 (ja) | 2013-12-30 | 2014-12-30 | パターニングされたメンブレン |
| EP14827247.9A EP3089764A1 (en) | 2013-12-30 | 2014-12-30 | Patterned membrane |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI20136336A FI126854B (fi) | 2013-12-30 | 2013-12-30 | Membraani, sen käyttö ja menetelmä membraanin valmistusta varten |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FI20136336A FI20136336A (fi) | 2015-07-01 |
| FI126854B true FI126854B (fi) | 2017-06-30 |
Family
ID=52347346
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI20136336A FI126854B (fi) | 2013-12-30 | 2013-12-30 | Membraani, sen käyttö ja menetelmä membraanin valmistusta varten |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20160325006A1 (fi) |
| EP (2) | EP3089765B1 (fi) |
| JP (2) | JP6576933B2 (fi) |
| CN (2) | CN105873621A (fi) |
| DK (1) | DK3089765T3 (fi) |
| FI (1) | FI126854B (fi) |
| WO (2) | WO2015101711A1 (fi) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3187195T3 (en) * | 2015-12-31 | 2019-01-14 | Upm Kymmene Corp | MEDICAL MULTILAYER PRODUCT INCLUDING NANOFIBRILLARY CELLULOSE AND A PROCEDURE FOR PRODUCING THEREOF |
| EP3228329B1 (en) * | 2016-04-06 | 2022-06-08 | UPM-Kymmene Corporation | A method for preparing a medical product comprising nanofibrillar cellulose and a medical product |
| WO2017214592A1 (en) * | 2016-06-09 | 2017-12-14 | Paul Gatenholm | Preparation of modified cellulose nanofibrils with extracellular matrix components as 3d bioprinting bioinks |
| JP6139754B1 (ja) * | 2016-06-17 | 2017-05-31 | 株式会社ユーグレナ | 細胞増殖促進剤 |
| FI127590B (fi) * | 2016-07-04 | 2018-09-28 | Teknologian Tutkimuskeskus Vtt Oy | Selluloosapohjainen kalvorakenne ja menetelmä sellaisen valmistamiseksi |
| JP6758621B2 (ja) * | 2016-10-17 | 2020-09-23 | 株式会社日本触媒 | 細胞培養用基材およびその製造方法、ならびにこれを利用した細胞培養容器および細胞培養方法 |
| EP3335695B1 (en) * | 2016-12-15 | 2020-02-05 | UPM-Kymmene Corporation | A method for freeze-drying hydrogel comprising nanofibrillar cellulose, a freeze-dried medical hydrogel comprising nanofibrillar cellulose, and a hydrogel comprising nanofibrillar cellulose |
| JP6866693B2 (ja) * | 2017-03-02 | 2021-04-28 | 王子ホールディングス株式会社 | シート |
| JP6907601B2 (ja) * | 2017-03-02 | 2021-07-21 | 王子ホールディングス株式会社 | 積層シート |
| WO2018165327A1 (en) * | 2017-03-08 | 2018-09-13 | Alafair Biosciences, Inc. | Hydrogel medium for the storage and preservation of tissue |
| WO2019010570A1 (en) * | 2017-07-10 | 2019-01-17 | The Governors Of The University Of Alberta | PATTERNED MICROFILTER MEMBRANE AND PREPARATION METHOD THEREOF |
| CN109381742B (zh) * | 2017-08-09 | 2022-05-03 | 国家纳米科学中心 | 基于图案化细菌纤维素的三维人工椎间盘及其制备方法和应用 |
| CN107638587A (zh) * | 2017-09-25 | 2018-01-30 | 凯斯蒂南京医疗器械有限公司 | 具有组织诱导功能的无疤痕再生医用敷料及其制备方法 |
| WO2019145795A2 (en) | 2018-01-26 | 2019-08-01 | Cellink Ab | Systems and methods for optical assessments of bioink printability |
| US11186736B2 (en) | 2018-10-10 | 2021-11-30 | Cellink Ab | Double network bioinks |
| US11826951B2 (en) | 2019-09-06 | 2023-11-28 | Cellink Ab | Temperature-controlled multi-material overprinting |
| EP3791864A1 (en) * | 2019-09-13 | 2021-03-17 | UPM-Kymmene Corporation | Method for preparing pharmaceutical composition and pharmaceutical composition |
| EP3816338A1 (en) * | 2019-10-31 | 2021-05-05 | UPM-Kymmene Corporation | Medical product and method for preparing thereof |
| SE544449C2 (en) * | 2019-12-23 | 2022-05-31 | Stora Enso Oyj | Method for manufacture of a patterned liquid repellent nanocellulosic film |
| CN111265709A (zh) * | 2020-03-20 | 2020-06-12 | 陈传华 | 一种儿科用防止肺炎病毒感染的伤口防护膜及其制备方法 |
| US20230310699A1 (en) * | 2020-06-10 | 2023-10-05 | The Australian National University | Haemostatic material |
| CN113249294B (zh) * | 2021-05-17 | 2022-09-27 | 北京化工大学 | 一种能够使细胞图案化生长的表面及其应用 |
| CN113952114B (zh) * | 2021-09-24 | 2022-09-09 | 北京科技大学 | 具有图案化可释放气体的多层纳米纤维敷料及其制备方法 |
| CN114848898B (zh) * | 2022-06-23 | 2023-07-21 | 点云生物(杭州)有限公司 | 一种基于3d打印工艺制造的人工骨支架及方法 |
| US20240091399A1 (en) * | 2022-09-09 | 2024-03-21 | Upm-Kymmene Corporation | Medical grade nanofibrillar cellulose hydrogel, a method for treating a subject in need of treatment of body with implantable material and a method for manufacturing the medical grade nanofibrillar cellulose hydrogel |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6602994B1 (en) * | 1999-02-10 | 2003-08-05 | Hercules Incorporated | Derivatized microfibrillar polysaccharide |
| EP1196206A1 (en) | 1999-07-09 | 2002-04-17 | Advanced Tissue Sciences, Inc. | Human naturally secreted extracellular matrix-coated device |
| US6202994B1 (en) * | 1999-11-23 | 2001-03-20 | William Spurlin | High energy spring for vibratory devices |
| US8277837B2 (en) * | 2006-01-11 | 2012-10-02 | Entegrion, Inc. | Hemostatic textile |
| US8728817B2 (en) * | 2007-05-04 | 2014-05-20 | University Of Virginia Patent Foundation | Compositions and methods for making and using laminin nanofibers |
| CA2741516A1 (en) * | 2008-11-07 | 2010-05-14 | Sofradim Production | Template for bacterial cellulose implant processed within bioreactor |
| US20100158985A1 (en) * | 2008-12-19 | 2010-06-24 | Xylos Corporation | Porous structures of microbial-derived cellulose for in vivo implantation |
| FI123988B (fi) * | 2010-10-27 | 2014-01-31 | Upm Kymmene Corp | Soluviljelymateriaali |
| US8906393B2 (en) * | 2011-01-26 | 2014-12-09 | Rutgers, The State University Of New Jersey | Biofilm inhibiting composition |
| GB2498265B (en) * | 2012-01-04 | 2015-04-08 | Procter & Gamble | Fibrous structures comprising particles and methods for making same |
| FI126055B (fi) * | 2012-05-14 | 2016-06-15 | Upm Kymmene Corp | Menetelmä kalvon valmistamiseksi fibrillisellusta ja fibrillisellukalvo |
-
2013
- 2013-12-30 FI FI20136336A patent/FI126854B/fi active IP Right Grant
-
2014
- 2014-12-30 US US15/109,068 patent/US20160325006A1/en not_active Abandoned
- 2014-12-30 EP EP14828042.3A patent/EP3089765B1/en active Active
- 2014-12-30 CN CN201480071655.6A patent/CN105873621A/zh active Pending
- 2014-12-30 WO PCT/FI2014/051061 patent/WO2015101711A1/en active Application Filing
- 2014-12-30 JP JP2016543668A patent/JP6576933B2/ja active Active
- 2014-12-30 CN CN201480071650.3A patent/CN106132447A/zh active Pending
- 2014-12-30 EP EP14827247.9A patent/EP3089764A1/en not_active Withdrawn
- 2014-12-30 DK DK14828042.3T patent/DK3089765T3/da active
- 2014-12-30 WO PCT/FI2014/051062 patent/WO2015101712A1/en active Application Filing
- 2014-12-30 JP JP2016543634A patent/JP6636926B2/ja active Active
- 2014-12-30 US US15/108,943 patent/US20160325008A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3089765B1 (en) | 2020-11-18 |
| US20160325006A1 (en) | 2016-11-10 |
| WO2015101712A1 (en) | 2015-07-09 |
| EP3089764A1 (en) | 2016-11-09 |
| US20160325008A1 (en) | 2016-11-10 |
| JP6576933B2 (ja) | 2019-09-18 |
| EP3089765A1 (en) | 2016-11-09 |
| DK3089765T3 (da) | 2020-12-07 |
| JP6636926B2 (ja) | 2020-01-29 |
| JP2017506923A (ja) | 2017-03-16 |
| JP2017506924A (ja) | 2017-03-16 |
| CN106132447A (zh) | 2016-11-16 |
| WO2015101711A1 (en) | 2015-07-09 |
| FI20136336A (fi) | 2015-07-01 |
| CN105873621A (zh) | 2016-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI126854B (fi) | Membraani, sen käyttö ja menetelmä membraanin valmistusta varten | |
| Movahedi et al. | Potential of novel electrospun core-shell structured polyurethane/starch (hyaluronic acid) nanofibers for skin tissue engineering: In vitro and in vivo evaluation | |
| Zhang et al. | Layered nanofiber sponge with an improved capacity for promoting blood coagulation and wound healing | |
| KR102661264B1 (ko) | 나노원섬유 셀룰로오스 생성물 및 그 제조 방법 | |
| Pal et al. | Bilayered nanofibrous 3D hierarchy as skin rudiment by emulsion electrospinning for burn wound management | |
| EP2575905B1 (en) | Chitosan biomimetic scaffolds and methods for preparing the same | |
| DK2958599T3 (en) | NANOFIBRILLARY POLYSACCHARIDE USED BY CONTROL AND PREVENTION OF CONTRACTION AND CREATION | |
| WO2007027849A2 (en) | Multiribbon nanocellulose as a matrix for wound healing | |
| US20230181791A1 (en) | method for treating deep wounds of dermis and/or below tissue | |
| Ghosh et al. | Single unit functionally graded bioresorbable electrospun scaffold for scar-free full-thickness skin wound healing | |
| JP2021079089A (ja) | 医療製品及びその作製方法 | |
| Bacakova et al. | Nanocellulose in biotechnology and medicine: Focus on skin tissue engineering and wound healing | |
| JP2021132629A (ja) | 細胞非接着性材料および細胞接着制御性材料 | |
| Tovar Carrillo | Regenerated Medicines of Cellulosic Hydrogels for Cytocompatibility of Tissue Skin and Biocompatibility | |
| CZ202132A3 (cs) | Prostředek pro hojení ran, způsob jeho výroby a použití | |
| WO2023230213A1 (en) | Keratin protein extracts, compositions, methods and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Patent granted |
Ref document number: 126854 Country of ref document: FI Kind code of ref document: B |